Jim Cramer Highlights That “Revvity’s the Cheapest in the Group”

Revvity, Inc. (NYSE:RVTY) is one of the stocks Jim Cramer recently discussed. Cramer highlighted the company’s cheap valuation compared to its group, as he said:

“Now, I’ve got two more smaller life science arms dealers to round out things. First one’s called Revvity. You might’ve seen that one trade. That’s the life science business that remained when PerkinElmer broke itself up about two and a half years ago. PerkinElmer sold its applied food and enterprise services business to a private equity firm, and that business took the PerkinElmer name with it. The remaining life sciences business, which remained publicly traded, was renamed Revvity.

Now, after a couple years of disappointing results where the stock went nowhere, Revvity finally posted some better-than-expected numbers in October, and management raised their full-year earnings forecast. It was a good solid result from a company that hasn’t really given us much in those recent years, and the stock’s gotten some traction since then. Revvity’s the cheapest in the group with the stock selling for around 21 times this year’s earnings estimates.”

A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels

Revvity, Inc. (NYSE:RVTY) provides instruments, reagents, software, and sequencing services used for genetic testing, disease screening, and diagnostic and research applications.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.